← All stocks

Enliven Therapeutics, Inc.

ELVN Scheduled selling only
CIK 0001672619 #1481 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$645.48K
$352.55K on a plan · $292.93K straight out of an exercise
Sold at will
$0.00
0 of 4 sales
Net
−$645.48K
$0.00 against sales at will

By person

10 insiders · 4 transactions

There is no salary here to measure against. Enliven Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Hohl Benjamin
CHIEF FINANCIAL OFFICER
$352.55K (2) scheduled
−$352.55K
40,036
0.0546%
$2.38M
Collins Helen Louise
CHIEF MEDICAL OFFICER
$292.93K (2) scheduled
−$292.93K
25,000
0.0341%
$1.48M
ORBIMED ADVISORS LLC entity
10% owner
6,555,102
8.95%
$389.02M
−14.8%
Kintz Samuel
PRESIDENT AND CEO
890,392
1.22%
$52.84M
−15.0%
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER
758,938
1.04%
$45.04M
−29.6%
Patel Anish
CHIEF OPERATING OFFICER
235,011
0.3207%
$13.95M
−31.7%
Heyman Richard A.
Director
146,320
0.1997%
$8.68M
−13.4%
Kunkel Lori Anne
Director
41,884
0.0572%
$2.49M
−8.8%
Ballal Rahul D.
Director
22,341
0.0305%
$1.33M
0.0%
Derynck Mika K
Director
0
0.0000%
$0.00
Insider
Date
Role
Action
Shares
Price
Amount
Hohl Benjamin
17 Aug 2026
CHIEF FINANCIAL OFFICER
Sold on a plan
1,388
$59.35
$82.38K
Hohl Benjamin
17 Aug 2026
CHIEF FINANCIAL OFFICER
Sold on a plan
4,630
$58.35
$270.17K

What was left out

Form 4 filings counted 2
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 2
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 5,000
History held since 16 Mar 2020